Evotec SE (NASDAQ:EVO - Get Free Report)'s share price traded down 3% during trading on Thursday . The company traded as low as $4.84 and last traded at $4.85. 4,094 shares were traded during trading, a decline of 97% from the average session volume of 139,651 shares. The stock had previously closed at $5.00.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on EVO shares. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Evotec in a report on Thursday, November 7th. Jefferies Financial Group downgraded shares of Evotec from a "buy" rating to a "hold" rating and cut their price target for the stock from $8.70 to $3.80 in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Evotec currently has an average rating of "Hold" and an average target price of $5.93.
Check Out Our Latest Research Report on EVO
Evotec Price Performance
The stock has a fifty day moving average price of $4.44 and a 200-day moving average price of $4.13. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
Institutional Investors Weigh In On Evotec
A number of large investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC purchased a new stake in Evotec during the 2nd quarter worth $87,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Evotec during the third quarter valued at about $104,000. Mediolanum International Funds Ltd purchased a new stake in shares of Evotec during the third quarter worth about $512,000. DCF Advisers LLC lifted its stake in shares of Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after acquiring an additional 67,156 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Evotec by 29.7% in the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock valued at $9,616,000 after purchasing an additional 602,858 shares during the last quarter. Institutional investors and hedge funds own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
